PolyPeptide Group AG is a specialized Contract Development & Manufacturing Organization (CDMO) focused on peptide- and oligonucleotide-based active pharmaceutical ingredients (APIs). Established with roots dating back to 1952 in Malmö, Sweden, it supports pharmaceutical and biotech companies by providing comprehensive services from pre-clinical development through commercial manufacturing stages. The company operates a global network of six GMP-certified facilities across Europe, the United States, and India, enabling it to deliver high-quality peptides for therapies targeting metabolic diseases like diabetes and obesity (including GLP-1 agonists), cancer, cardiovascular, and neurological disorders. PolyPeptide Group AG has manufactured over 1,000 GMP-grade peptides, emphasizing innovation, excellence, and trust as core values to foster long-term customer partnerships. Its broad portfolio also includes generics, cosmetics, and emerging capabilities in oligonucleotides and neoantigen peptides for personalized cancer treatments, positioning it as a market leader in the fast-growing peptide therapeutics sector with significant exposure to high-demand therapeutic areas. Employing around 1,400 professionals, PolyPeptide Group AG drives sustainable manufacturing advancements and invests heavily in capacity expansion to meet evolving market needs.